Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03150576 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Study acronym: PARTNER
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 14, 2022 (before its estimated June 2024 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jan 2022 to Jun 2024v2 Show 6 more changesShow less
    • Enrollment target: 527 to 780
    • Study sites: 1 to 30
    • Study completion date: Jan 2032 to Jun 2034
    • Secondary endpoints: 12 to 13
    • Study description expanded, about 40 words
    • Study title shortened, about 3 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).
Trial Details
NCT Number NCT03150576
Lead Sponsor Cambridge University Hospitals NHS Foundation Trust
Collaborators: AstraZeneca, Cancer Research UK
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms, Triple Negative Breast Neoplasms
Enrollment 780 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov